This fellowship aims to develop evidence-based clinical and public health approaches to the control of multi-drug resistant tuberculosis. Projects include identifying optimal treatment approaches to drug resistant tuberculosis by using meta-analyses; analysing the cost-effectiveness of strategies to prevent drug resistant tuberculosis; understanding transmission of drug resistance within households and implementing a major clinical trial of antibiotic therapy to prevent the disease.
Prof Paterson is an Infectious Diseases Physician studying the molecular and clinical epidemiology of infections with Gram negative bacteria producing newer beta-lactamases.
I am a public health physician and medical parasitologist determining the mechanism of clinical immunity to malaria, and working on the development of vaccines and therapies against malaria.
Immunisation is second only to clean water and sanitation as a life-saving activity. Vaccine safety is considered to be very important by the general public, the media and the health professions. With so many diseases controlled and now rare, the safety of vaccines assumes greater importance. Research is needed on new and safer vaccines, using e.g. a needle-free approach, against old foes, like influenza, and new enemies (like MERS) with vaccine safety more important than ever.
Loop-mediated Isothermal Amplification(LAMP): A Novel Tool For The Diagnosis Of Mixed Malaria Infections In Elimination Settings
Funder
National Health and Medical Research Council
Funding Amount
$101,877.00
Summary
The malaria elimination agenda will require the development of novel, field applicable diagnostic tools to detect asymptomatic carriers of P.falciparum and non-falciparum malaria infections. Loop-mediated isothermal amplification (LAMP) has been demonstrated to be a novel, sensitive, specific nucleic acid amplification technique. My project aims to optimise LAMP into a high-throughput field applicable molecular diagnostic tool capable of diagnosing malaria in elimination settings
Alternative Pneumococcal Vaccination Schedules For Infants In Fiji And Pneumococcal Epidemiology
Funder
National Health and Medical Research Council
Funding Amount
$50,214.00
Summary
The aim of this study is to find a safe and epidemiologically appropriate pneumococcal vaccination strategy for resource poor countries. A single, blind open-label randomized Phase II study is underway in Fiji documenting the safety, immunogenicity and impact on pneumococcal carriage of various pneumococcal vaccination regimens combining 1, 2, or 3 doses of 7-valent pneumococcal conjugate vaccine (PCV) in infancy followed by a single booster dose of 23-valent pneumococcal polysaccharide vaccine.
Implementation Of Highly Effective Therapy For Hepatitis C
Funder
National Health and Medical Research Council
Funding Amount
$569,219.00
Summary
Hepatitis C is a major public health issue in Australia, and globally, with escalating liver disease burden. Highly effective interferon-free HCV regimens will be available from 2016 and have the potential to provide one of the greatest advances in clinical medicine in recent decades. Development of implementation strategies for new HCV therapies, particularly for highly marginalised populations including people who inject drugs and prisoners, is crucial to provide broad public health impact.